I agree that this site is using cookies. You can find further informations here.
X
Obr, Aleš
48  results:
Search for persons X
?
1

Ibrutinib in mantle cell lymphoma: a real-world retrospecti..:

Obr, Ales ; Benesova, Katerina ; Janikova, Andrea...
Annals of Hematology.  102 (2022)  1 - p. 107-115 , 2022
Link: https://doi.org/10.1007/..
 
?
2

Polatuzumab vedotin plus bendamustine and rituximab in pati..:

Vodicka, Prokop ; Benesova, Katerina ; Janikova, Andrea...
European Journal of Haematology.  109 (2022)  2 - p. 162-165 , 2022
Link: https://doi.org/10.1111/..
 
?
3

Long-term outcomes from the Phase II L-MIND study of tafasi..:

Duell, Johannes ; Maddocks, Kami J. ; González-Barca, Eva...
Haematologica.  106 (2021)  9 - p. 2417-2426 , 2021
Link: https://doi.org/10.3324/..
 
?
4

Long-term outcomes from the phase II L-MIND study of tafasi..:

Duell, Johannes ; Maddocks, Kami J. ; González-Barca, Eva...
Haematologica.  , 2021
Link: https://doi.org/10.3324/..
 
?
5

COVID-19 in 96 Patients With Hematologic Disease: The First..:

Čerňan, Martin ; Szotkowski, Tomáš ; Obr, Aleš...
Clinical Lymphoma Myeloma and Leukemia.  21 (2021)  9 - p. 606-612 , 2021
Link: https://doi.org/10.1016/..
 
?
6

CD19 expression is maintained in DLBCL patients after treat..:

Duell, Johannes ; Obr, Aleš ; Augustin, Marinela...
Leukemia & Lymphoma.  63 (2021)  2 - p. 468-472 , 2021
Link: https://doi.org/10.1080/..
 
?
7

Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapse..:

Kolstad, Arne ; Illidge, Tim ; Bolstad, Nils...
Blood Advances.  4 (2020)  17 - p. 4091-4101 , 2020
Link: https://doi.org/10.1182/..
 
?
8

ABCL-170: Long-Term Outcomes from the Phase II L-MIND Study..:

Salles, Gilles ; Duell, Johannes ; González-Barca, Eva...
Clinical Lymphoma Myeloma and Leukemia.  20 (2020)  - p. S267-S268 , 2020
Link: https://doi.org/10.1016/..
 
?
9

Concurrent TP53 and CDKN2A Gene Aberrations in Newly Diagno..:

Malarikova, Diana ; Berkova, Adela ; Obr, Ales...
Cancers.  12 (2020)  8 - p. 2120 , 2020
Link: https://doi.org/10.3390/..
 
?
10

A highTP53mutation burden is a strong predictor of primary ..:

Obr, Ales ; Klener, Pavel ; Furst, Tomas...
British Journal of Haematology.  191 (2020)  5 - p. , 2020
Link: https://doi.org/10.1111/..
 
?
11

Rituximab maintenance significantly prolongs progression‐fr..:

Klener, Pavel ; Salek, David ; Pytlik, Robert...
American Journal of Hematology.  94 (2018)  2 - p. , 2018
Link: https://doi.org/10.1002/..
 
?
12

TP53 Mutation and Complex Karyotype Portends a Dismal Progn..:

Obr, Aleš ; Procházka, Vít ; Jirkuvová, Andrea...
Clinical Lymphoma Myeloma and Leukemia.  18 (2018)  11 - p. 762-768 , 2018
Link: https://doi.org/10.1016/..
 
?
13

Alternating R‐CHOP and R‐cytarabine is a safe and effective..:

Klener, Pavel ; Fronkova, Eva ; Belada, David...
Hematological Oncology.  36 (2017)  1 - p. 110-115 , 2017
Link: https://doi.org/10.1002/..
 
?
14

Ibrutinib in mantle cell lymphoma: a real-world retrospecti..:

Obr, Ales ; Benesova, Katerina ; Janikova, Andrea...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807478/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
15

COVID-19 infection in adult patients with hematological mal..:

Pagano, Livio ; Salmanton-García, Jon ; Marchesi, Francesco...
qt8j34c3vj.  , 2021
Link: https://escholarship.org..
 
1-15